Blood-brain barrier permeability changes as early biomarkers for neurodegeneration
PARTIALLY FILLED
What is the evidence that blood-brain barrier (BBB) permeability changes serve as early biomarkers for neurodegeneration?
Focus areas:
- CSF biomarker panels for BBB dysfunction (tight junction proteins like claudin-5, zonula occludens-1; pericyte markers like PDGFR-beta)
- Blood-based BBB permeability indicators (S100B, NFL, GFAP in plasma vs CSF)
- Dynamic contrast-enhanced MRI measures of BBB leakage as early AD/PD markers
- Relationship between BBB disruption and neurovascular uncoupling preceding motor/cognitive symptoms
- Comparative utility of BBB permeability markers vs amyloid/tau PET for early detection
Landscape Summary:
Blood-brain barrier permeability changes as early biomarkers for neurodegeneration is a 0.8 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.506.
Status: partially_filled.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Blood-brain barrier permeability changes as early biomarkers for neurodegeneration — INVOKE-2 (completed)